Articles
<![CDATA[Manfaat Terapi Tambahan Vitamin pada Pasien Nyeri Neuropati Diabetika ]]>
<![CDATA[Edenia Asisaratu]]>;
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Esdras Ardi Pramudita]]>
<![CDATA[ Jurnal Farmasi Udayana Vol. 12, No 1, Tahun 2023 ]]>
Publisher : <![CDATA[Departement of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.24843/JFU.2023.v12.i01.p12
<![CDATA[Background: Painful Diabetic Neuropathy is one of the most common complications of Diabetes Mellitus, which becomes a burden that necessitates optimal treatment. Current treatment is symptomatic therapy with glycemic index control but it has yet to reach the best results. Supplementing with vitamins B and D has been shown to provide significant pain relief in previous studies. Methodology: This was a retrospective cohort study. A total of 107 subjects were sampled using consecutive sampling method and they were given either symptomatic therapy or symptomatic therapy plus vitamins for three months. The pain scale was measured using Neuropathic Pain Scale. Results: The subjects were compared in three comparison groups. Subjects who received symptomatic therapy plus vitamin had the greatest pain reduction (39,50±14,222) (p=0,000) in the first comparison group. Subjects who received symptomatic therapy plus vitamin B combination and vitamin D 1000 IU had the greatest pain reduction (53,00±6,749) (p=0,000) in the second comparison group. Subjects who received symptomatic therapy plus vitamin D 1000 IU had the greatest pain reduction (44,00±8,944) (p=0,088) in the third comparison group. Conclusions: Additional vitamin therapy resulted in a significantly greater pain reduction than symptomatic therapy alone. There was no significant difference in pain reduction between the vitamin D 400 IU addition and vitamin D 1000 IU addition. Keywords: painful diabetic neuropathy; pain intensity; vitamin B; vitamin D]]>
<![CDATA[Terapi Tambahan Predimenol pada Osteoartritis: Serial Laporan Kasus ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>
<![CDATA[ MEDICINUS Vol. 37 No. 1 (2024): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/wdj43n05
<![CDATA[Osteoartritis merupakan suatu kelainan muskuloskeletal yang dapat menyebabkan penurunan kualitas hidup dan terganggunya aktivitas hidup sehari-hari (activities of daily living/ADL). Degenerasi sendi yang terjadi pada osteoartritis dapat menimbulkan beberapa manifestasi klinis seperti nyeri, bengkak, kaku, dan terbatasnya pergerakan pada sendi, yang menyebabkan penderita osteoartritis mengalami hambatan dalam menjalani aktivitas sehari-hari. Tulisan ini melaporkan serial kasus pasien osteoartritis KL2−KL3 dengan berbagai penyakit penyerta. Terapi awal yang diberikan adalah paracetamol 500 mg tiga kali sehari yang dikombinasikan dengan terapi tambahan predimenol 200 mg dua kali sehari. Pada observasi yang dilakukan setelah terapi selama dua minggu, kami mengamati perbaikan yang signifikan dalam penurunan intensitas nyeri dan mobilitas. Predimenol juga dilaporkan dapat ditoleransi dengan baik pada semua pasien.]]>
<![CDATA[The Use of Predimenol After Simple Pain Intervention in High-Risk Patients: A Case Series ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Aditya Aristo Marvel Nugroho]]>
<![CDATA[ MEDICINUS Vol. 38 No. 1 (2025): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/4fb0jj22
<![CDATA[Effective pain management is a common challenge in clinical practice, whether it involves prescription medications or over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs). The use of NSAIDs has been linked to various risks, including cardiovascular (CV), kidney, and gastrointestinal (GI) complications. Certain group of patients face a higher likelihood of these risks. NSAIDs consumptions have been shown to cause a modest, but steady increase in the chance of experiencing CV events and developing kidney problems. In this case series, we reported a series of inflammatory pain cases. Following simple pain intervention, we administered paracetamol and Predimenol over a 10 day period. The use of Predimenol was proven to be effective in alleviating pain without causing any notable adverse effects. ]]>
<![CDATA[The Benefit of DLBS3233 as Add-on Therapy for Symptomatic Painful Diabetic Neuropathy: Case Series ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Abraham Al Jody]]>;
<![CDATA[Nicholas Adriel Pinzon]]>
<![CDATA[ MEDICINUS Vol. 38 No. 2 (2025): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/rhjkcb40
<![CDATA[Symmetrical painful diabetic neuropathy (PDN) is a highly prevalent form of diabetic peripheral neuropathy with significant morbidity. Despite its high prevalence, the optimal treatment of this condition remains a clinical challenge. There was an emergence need for add-on therapy that more focused on the dimensions of inflammation and toxic oxidative stress.Previous evidences from placebo-controlled studies have shown that opioids, antiepileptic, and antidepressant drugs are effective for alleviating PDN symptoms. In many cases, safety issues regarding potential side effects of those drugs limit the optimal use of the medications. We report case series of painful diabetic neuropathy in type 2 diabetic patients. DLBS3233 was given as add-on therapy to standard oral antidiabetic medication or insulin and adjuvant analgesics for all patients. After 3 months follow up, there was modest pain reduction and improvement in blood glucose control in allpatients. DLBS3233 was well tolerated in all patients. ]]>
<![CDATA[RAMSAY HUNT SYNDROME: A CASE REPORT ]]>
<![CDATA[Gavrila, Priska Gian]]>;
<![CDATA[Rizaldy Taslim Pinzon]]>
<![CDATA[ Acta Neurologica Indonesia Vol. 3 No. 01 (2025): Acta Neurologica Indonesia ]]>
Publisher : <![CDATA[Departemen Neurologi Fakultas Kedokteran Universitas Indonesia ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.69868/ani.v3i01.47
<![CDATA[Introduction : Ramsay Hunt Syndrome or Herpes Zoster Oticus, is a rare and severe complication of varicella zoster virus reactivation. The syndrome consists of: the presence of vesicles in the auditory canal, otalgia, and ipsilateral facial paralysis. If this condition was not treated properly, the full recovery chances only occurs in as little at 20% of cases. Early treatment with steroid and antiviral that started within 72 hours will improve the prognosis. We report a rare case of Ramsay Hunt Syndrome that occurs after 20 days of rash eruption. Case Report : We report a case of 56-year-old male that referred because of painful herpetic neuralgia and facial nerve palsy. The patient developed right-sided facial burning pain that followed with the presence of erythematous, vesicular rash erupted at fore head and ear. Exam showed a similar rash along the auricle and the external auditory canal. On day 24, the patient woke up with partial right-sided facial paralysis and he was referred to the neurology clinic. In the neurology clinic, Ramsay Hunt Syndrome was diagnosed. Discussion : We report a rare case of Ramsay Hunt Syndrome. The mechanism involve reactivation of dormant varicella zoster virus. After primary varicella infection, the virus may stay dormant in sensory dorsal root ganglia. The reactivation causes shingles, ipsilateral vesicular eruption that limited with dermatomal distribution. Conclusion : We report a rare case of Ramsay Hunt Syndrome. This was a very rare complications of varicella zoster reactivation. Keywords: Neuralgia1; Facial Palsy2; Ramsay Hunt3 ; Varicella Zoster4]]>
<![CDATA[The Use of Predimenol for Nonspecific, Mild-to-Moderate Headache: Case Series ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Andre Darmawan Wiyono]]>
<![CDATA[ MEDICINUS Vol. 38 No. 3 (2025): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/s2zpt094
<![CDATA[Headache is a major healthcare concern worldwide. Adequate headache management is a widespread clinical concern, either using prescription or over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs). The use of NSAIDs for headache has been associated with several risk of cardiovascular (CV), renal, and gastrointestinal (GI) complications.There were certain patients are at increased risk of using these agents. The use of NSAIDs results in small but consistent increases in the risk of cardiovascular events and kidney problem. We report case series of primary headache conditions with GI comorbidities. After careful history taking, neurological examination, and imaging, we used paracetamol and Predimenol for one week. The use of Predimenol was effective in reducing headache severity without any significant side effects. ]]>
<![CDATA[The Gastroprotective Effect of DLBS2411 for High-Risk Gastrointestinal Patients: Case Series in Inflammatory Pain Condition ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Abraham Al Jody]]>;
<![CDATA[Nicholas Adriel Pinzon]]>
<![CDATA[ MEDICINUS Vol. 38 No. 4 (2025): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/6197xj25
<![CDATA[Chronic pain is a common and distressing problem for the population. The cyclooxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in managing acute and chronic pain. Research has provided a greater understanding of the risks of gastrointestinal, cardiovascular, and renal events associated with NSAID use. Proton pump inhibitors (PPIs) are widely prescribed due to their gastroprotective effects in NSAID users. However, PPIs also have several acid-inhibition-related and unrelated adverse effects that limit their use in high-risk patients. We report five patients suffering from painful inflammatory pain (flare rheumatoid arthritis, painful knee bursitis, and osteoarthritis). In this case series we evaluate the use of DLBS2411 as an alternative to PPIs. Our study suggests that DLBS2411 can be a safe alternative to PPIs for gastrointestinal high-risk patients who require anti-inflammatory agents.]]>
<![CDATA[The Benefit of DLBS1033 for Deep Vein Thrombosis in A Hemorrhagic Stroke Patient: A Case Report ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Ivana Prasetianingtyas]]>
<![CDATA[ MEDICINUS Vol. 38 No. 10 (2025): MEDICINUS ]]>
Publisher : <![CDATA[PT Dexa Medica ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.56951/yvsv1k10
<![CDATA[Background: Deep vein thrombosis (DVT) is a significant complication in patients with hemorrhagic stroke, primarily due to prolonged immobility. Although anticoagulants are routinely used for DVT prophylaxis in stroke patients, its application in hemorrhagic stroke remains controversial due to the increased risk of intracranial bleeding. This resulting in a challengingbalance between preventing DVT and avoiding further hemorrhage. DLBS1033, a bioactive protein fraction from the earthworm Lumbricus rubellus, demonstrated antithrombotic, thrombolytic, and antiplatelet aggregation activities, offeringa potential alternative therapeutic approach in such cases.Case report: A 68-year-old male with history of chronic hypertension and well-controlled type 2 diabetes mellitus presented to the emergency department with drowsiness and left-sided hemiparesis, subsequently diagnosed as intracerebral hemorrhage. On the sixth day of hospitalization, the patient developed DVT. DLBS1033 was administered as part of themanagement strategy.Conclusions: This case report demonstrates the effective and safe use of DLBS1033 in managing DVT for patient with hemorrhagic stroke. DLBS1033 is considered a potential promising agent for treating thrombus-related diseases.]]>
<![CDATA[Acute Hypokalemia Related with Thyrotoxicosis Periodic Paralysis: A Case Report ]]>
<![CDATA[Kadek Reisya Sita Damayanti]]>;
<![CDATA[Rizaldy Taslim Pinzon]]>
<![CDATA[ Acta Neurologica Indonesia Vol. 2 No. 02 (2024): Acta Neurologica Indonesia ]]>
Publisher : <![CDATA[Departemen Neurologi Fakultas Kedokteran Universitas Indonesia ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.69868/ani.v2i02.26
<![CDATA[Introduction : Hypokalemia paralysis is a rare condition. Thyrotoxic periodic paralysis (TPP) is a condition of hyperthyroidism characterized with acute muscle weakness and hypokalemia. TPP is commonly found in young Asian male. TPP is an uncommon clinical entity and might be a life threatening complication of thyrotoxicosis. We report a rare case of TPP with ECG abnormality related with severe hypokalemia. Case Report : A-21-year old Javanese male was presented to emergency department with acute onset of lower bilateral extremities weakness with proximal muscle predominant. Weakness progressed to his bilateral upper limb. Patient denied any significant trauma, vomiting, diarrhea, chest pain. Patient was fully conscious. Neurological examination revealed four limb weakness (lower limb muscle strength 2 from 5 scale MRC), diminished deep tendon reflexes, and intact sensory. Laboratory were remarkable for severe hypokalemia of 1.86 mEq/L. Further tests showed low TSH (0.022 mU/L), increased FT4 (23,68 mmol/L). ECG test showed abnormality related with hypokalemia. Thyroid ultrasound revealed multiple thyroid swelling, mass, and calcification. Patient was admitted to ICU and administered with 25mEq Potassium IV. Hypokalemia resolved after 3 days (Serum Potassium 3.76 mEq/L), followed by normal ECG feature without any AV block. He was discharged without any neurological abnormaliy. Conclusion : We report a rare case of acute onset paralysis and markedly low potassium level and high free T4 in previously health Asian male. This case highlights the paralysis related with hyperthyroidism that resolved completely following potassium replacement. Keywords: hypokalemia; paralysis; hyperthyroid; thyrotoxicosis periodic paralysis]]>
<![CDATA[A Familial Hypokalemic Periodic Paralysis : A Case Report ]]>
<![CDATA[Rizaldy Taslim Pinzon]]>;
<![CDATA[Larasati, Yutta]]>
<![CDATA[ Acta Neurologica Indonesia Vol. 2 No. 03 (2024): Acta Neurologica Indonesia ]]>
Publisher : <![CDATA[Departemen Neurologi Fakultas Kedokteran Universitas Indonesia ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.69868/ani.v2i03.36
<![CDATA[Hypokalemic periodic paralysis is characterized by recurrent attacks of skeletal muscle weakness with related hypokalaemia which is a rare genetic disorder. There might be a limited weakness for some groups of muscle, or it might appear as severe muscle paralysis. The muscle cells increase the uptake of potassium, hence the decreasing of potassium’s mechanism. The case of a clinically diagnosis familial hypokalaemia periodic paralysis in a 9-year-old boy that we report is established in this proband that settle the consensus diagnosis criteria for primary hypokalaemia periodic paralysis according to previous review that’s been published. Key words: paralysis-hypokalemia-periodic-familial.]]>
